Best Health Care Grants in American Samoa

The Global Technology Industry Association (GTIA) Grant supports nonprofits and schools leveraging technology to enhance lives in under-resourced communities. GTIA provides funding for innovative solutions addressing challenges like broadband access and educational equity. Eligible applicants are encouraged to apply, especially those referred by GTIA members. Key focus areas include educational technology, bridging the digital divide, and workforce initiatives that promote equitable access to resources and opportunities.

The 2027 Market Access Program (MAP) by USDA/FAS provides financial assistance to participants for marketing and promoting U.S. agricultural commodities internationally. This competitive program aims to enhance export opportunities for a wide range of agricultural products, excluding tobacco. Eligible participants can benefit from shared costs to increase their global market presence, thereby supporting U.S. agriculture and expanding trade.

The DICE program, funded by the US DOD's Advanced Research Projects Agency, aims to develop decentralized AI coordination and control algorithms. This initiative focuses on creating a scalable and resilient network of AI agents capable of executing long-term missions in challenging environments while ensuring human oversight. By leveraging principles of self-organization, DICE seeks to enhance the adaptability and predictability of AI behavior, promoting robust outcomes akin to the internet's decentralized architecture.

The 2027 Quality Samples Program, funded by the USDA's Foreign Agricultural Service, aims to enhance U.S. agricultural exports by providing potential foreign importers with samples of high-quality commodities. This initiative seeks to foster better market understanding and appreciation for U.S. products, ultimately promoting greater export opportunities for American producers. By supporting this program, U.S. entities can effectively showcase their agricultural offerings on a global stage.

The U.S. Department of Agriculture's Foreign Agricultural Service announces the 2027 Emerging Markets Program to support U.S. agricultural exports. This initiative aims to develop and expand markets for U.S. agricultural commodities, fostering cooperation and information exchange between U.S. agricultural institutions and emerging markets. Eligible U.S. entities can assess food and rural business systems, recommend enhancements, and identify specific projects to improve market effectiveness and reduce trade barriers.

The WaterSMART Cooperative Watershed Management Program offers funding to eligible entities for developing local solutions to water management issues. This initiative supports watershed group development, restoration planning, and project design, promoting stakeholder cooperation and improving water reliability. It aligns with key priorities from the Trump administration, addressing complex water challenges and enhancing federal grant oversight. By facilitating these efforts, the program aims to stretch limited water resources and foster collaborative solutions among diverse stakeholders.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is inviting applications for the Clinical Trial Cooperative Agreement Program. This funding opportunity supports investigator-initiated, interventional clinical trials at various phases. Initial funding will facilitate the preparation needed to start trials, with successful milestones leading to further support. NIAMS emphasizes hypothesis-driven trials that promise significant clinical impact within its research mission.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is launching a funding opportunity for Exploratory Clinical Trials Grants. This program aims to support innovative clinical trials that enhance the understanding and treatment of arthritis and other musculoskeletal and skin conditions. Research proposals should focus on early-stage trials, including first-in-human studies, dose-finding, and biomarker evaluation. The initiative encourages the translation of promising laboratory findings into effective clinical practices, ultimately improving patient outcomes.

The Systems-Based Approaches to Improve Patient Safety program aims to enhance patient safety by prioritizing healthcare worker safety and well-being. By focusing on systemic improvements, this initiative seeks to create a safer healthcare environment, recognizing that worker safety is integral to patient safety. The funding opportunity encourages innovative proposals that bring new insights from healthcare professionals, ultimately supporting AHRQ's mission to strengthen the patient safety movement.

The NEI Small Business Innovation Research (SBIR) Cooperative Agreement aims to support small businesses in conducting early-stage clinical trials that pose greater than minimal risk. The program focuses on Phase I and II trials designed to evaluate interventions for vision disorders. Key deadlines for applications include January 30, 2024, and May 24, 2024, among others. Applicants are encouraged to consult with NEI staff prior to submission to ensure alignment with funding opportunities.

The Short-Term Research Education Program (R25) by the NIH aims to enhance diversity in health-related research by supporting educational activities. This program focuses on providing research experiences for individuals from underrepresented groups, enriching their opportunities in the biomedical field. Applications are due by 5 PM local time, with optional Letters of Intent encouraged 30 days prior to the proposal deadline. The goal is to cultivate a diverse research workforce essential for addressing health disparities.

The Alcohol Research-Related Resource Award (R24 Clinical Trial Not Allowed) aims to support investigator-initiated resources that enhance biomedical research on a national level. Through this non-hypothesis-driven grant, essential data, materials, and services will be provided to facilitate progress in the alcohol research community. The resources must be available to qualified investigators and should not replicate existing commercial offerings, ensuring high-quality and cost-efficient support for diverse research activities.

The Fiscal Year 2027 Expanding Nutrition Services (ENS) initiative aims to enhance access to nutrition services through HRSA-funded health centers. This funding is designed to support interventions that prevent, manage, and treat various health conditions via nutritional approaches. Eligible applicants are required to demonstrate an increase in the number of patients receiving nutrition services or the number of visits, thereby promoting better health outcomes for communities.

The NIH R25 program aims to enhance inclusivity in research education by supporting activities that encourage individuals from diverse backgrounds to pursue careers in substance use and addiction sciences. This initiative focuses on skills development courses and research experiences, particularly targeting underrepresented groups in biomedical and behavioral sciences. Applications are due by 5:00 PM local time of the applicant organization, with optional Letters of Intent encouraged 30 days prior to the full proposal deadline.

The DoW Rare Cancers Concept Award for FY26 promotes groundbreaking ideas in rare cancer research. This award encourages innovative applications that explore novel courses of investigation without requiring preliminary data. Unique to this program is the prohibition against mentioning the Principal Investigator or collaborators in the proposal materials, ensuring an unbiased review process. This funding opportunity aims to advance scientific discovery in the rare cancer domain.

The NINDS Exploratory Clinical Trials for Small Business (R41/R42) program supports Small Business Concerns in conducting investigator-initiated exploratory clinical trials. This funding opportunity emphasizes projects that align with the NINDS mission, evaluating diverse products including drugs, biologics, and devices. Only STTR Phase II and Fast-Track applications are eligible, fostering innovation in neurological disorder treatments. Applications are due by 5:00 PM local time, with optional Letters of Intent encouraged 30 days prior to the deadline.

The NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) grant supports small businesses in conducting innovative clinical trials relevant to neurological disorders. This funding opportunity encourages investigator-initiated projects evaluating drugs, devices, and therapies aligned with NINDS goals. Applications are accepted only from SBIR Phase II and Fast-Track applicants, with a submission deadline of 5:00 PM local time. Letters of Intent are encouraged 30 days prior to the full proposal deadline.

The National Institute of Nursing Research (NINR) plans to publish a funding opportunity announcement for Community-Partnered Nursing Research Centers (P20 Clinical Trial Optional). This initiative aims to strengthen nursing-led programs that foster community-partnered research addressing significant health issues. By enhancing interdisciplinary research capacities, the program will establish centralized resources in nursing schools, build expertise in community partnerships, and support nurse-led teams in developing, implementing, and evaluating impactful research projects.

The Miniaturization and Automation of Tissue Chip Systems (MATChS) initiative by the NIH aims to advance biomedical research through the development of automated tissue chip platforms. This program encourages small businesses to propose innovative technologies that enhance data acquisition and analysis while minimizing manual handling. Funded projects will create efficient, miniaturized systems vital for drug development and other research applications. Collaboration with NIH staff is expected to ensure milestones and commercial pathways are effectively established.

The DoW Lupus Transformative Vision Development Award supports planning and pilot studies aimed at generating preliminary data for future interventional lupus research. It encourages collaboration with lupus consumer advocates and allows for phase 0/1 clinical trials. However, phase 2/3 trials and animal studies are not permitted. Successful studies may lead to further funding through the Lupus Research Program. This initiative is critical for advancing lupus research and improving patient outcomes.

The DoW Lupus Impact Award, funded by the US Army Medical Command, aims to support innovative research that can significantly advance the understanding and treatment of lupus. This award focuses on high-risk, high-reward projects that align with the FY26 Lupus Research Program priorities. Notably, it does not permit clinical trials and limits applicants to one submission per mechanism, encouraging fresh and impactful ideas in lupus research.

The FY26 Lung Cancer Research Program's Idea Development Award supports innovative, high-risk research aimed at significant breakthroughs in lung cancer treatment. It encourages new concepts in their early stages, requiring preliminary data to demonstrate feasibility, although not necessarily from lung cancer studies. This program also features a New Investigator category, allowing early-career researchers to compete separately for funding, fostering a diverse range of impactful investigations.

The Lung Cancer Patient-Centered Outcomes and Survivorship Award (PCOSA) aims to enhance health outcomes for lung cancer patients by promoting patient-centered research. This FY26 initiative encourages projects that address key areas of survivorship and requires the involvement of lung cancer survivors or caregivers in research teams. Additionally, it supports both translational and clinical research, including pilot clinical trials, to improve the overall patient experience.

The Lung Cancer Translational Research Award (TRA) for FY26 supports innovative translational research aimed at transforming promising lung cancer ideas into clinical applications. This award emphasizes advanced preclinical studies and pilot clinical trials of novel interventions, addressing critical research areas within the Lung Cancer Research Program. Applicants can choose between two funding levels to advance their impactful studies, thereby contributing to significant advancements in lung cancer treatment.

The FY26 Melanoma Research Program Focused Program Award for Rare Melanomas supports multidisciplinary research initiatives aimed at addressing critical questions in rare melanomas. This award requires collaboration between an Initiating Principal Investigator and up to two Partnering PIs, with the inclusion of a rare melanoma survivor or patient advocate in the project team. Approximately $5.6M is allocated to fund two awards, each capped at $2.8M, over a maximum performance period of four years.

The Melanoma Research Program Melanoma Academy Scholar Award supports early career investigators within seven years of their initial faculty appointment. This unique virtual academy fosters collaboration among established researchers and Scholars, focusing on research and career potential in melanoma. With approximately $1.54M allocated to fund two Scholar Awards, each capped at $0.77M, the maximum performance period is three years, and funding is expected to be available until September 30, 2032.